

Treatment Naïve (unfavorable baseline treatment characteristics)

# Ledipasvir-Sofosbuvir +/- 3<sup>rd</sup> DAA in HCV Genotype 1 NIAID SYNERGY: Genotype 1

Kohli A, et al. Lancet. 2015;385:1107-13.


# Ledipasvir-Sofosbuvir +/- [GS-9669 or GS-9451] in Naïve GT1 NIAID SYNERGY GT-1 Trial: Features

## NIAID SYNERGY Trial

- **Design:** Open-label, phase 2a, using fixed dose ledipasvir-sofosbuvir alone or in combination with either GS-9669 (non-nucleoside NS5B inhibitor) or GS-9451 (NS3/4A protease inhibitor) in treatment-naïve GT 1
- **Setting:** single site, United States
- **Entry Criteria**
  - 18 years of age or older
  - Chronic HCV Genotype 1
  - Treatment naïve
  - HCV RNA  $\geq 2,000$  IU/mL
  - Patients in 6 week group excluded if cirrhotic
- **Primary End-Point:** SVR12

# Ledipasvir-Sofosbuvir +/- [GS-9669 or GS-9451] in Naïve GT1 NIAID SYNERGY GT-1 Trial: Features

Week 0 6 12 18 24



**Abbreviations:** LDV-SOF= ledipasvir-sofosbuvir

## Drug Dosing

Ledipasvir-sofosbuvir (90/400 mg): fixed dose combination; one pill once daily

GS-9669: 500 mg once daily


GS-9451: 80 mg once daily

# Ledipasvir-Sofosbuvir +/- [GS-9669 or GS-9451] in Naïve GT1 NIAID SYNERGY GT-1 Trial: Participants

Baseline Characteristic	LDV-SOF x 12 weeks (n=20)	LDV-SOF + GS-9669 x 6 weeks (n=20)	LDV-SOF + GS-9451 x 6 weeks (n=20)
Age, mean	57	54	54
Male, %	70	65	80
Black, %	80	95	90
White, %	20	5	10
HCV genotype, %			
1A	55	70	85
1B	45	30	15
HCV RNA >800,000 IU/ml, %	75	65	70
IL28B CT/TT, %	75	90	75
Advanced fibrosis, %			
Knodell score 3	25	25	25
Knodell score 4	15	0	0


Source: Kohli A, et al. *Lancet*. 2015;385:1107-15.

# Ledipasvir-Sofosbuvir +/- [GS-9669 or GS-9451] in Naïve GT1 NIAID SYNERGY GT-1 Trial: Viral Kinetics



# Ledipasvir-Sofosbuvir +/- [GS-9669 or GS-9451] in Naïve GT1 NIAID SYNERGY GT-1 Trial: Results

## NIH SYNERGY: SVR 12 by Treatment Regimen



\*1 patient relapsed 2 weeks after completion of treatment

^1 patient lost to follow-up after reaching SVR at 4 weeks

# Ledipasvir-Sofosbuvir +/- [GS-9669 or GS-9451] in Naïve GT1 NIAID SYNERGY GT-1 Trial: Interpretation

**Interpretation:** “In this small proof-of-concept study, two different three-drug regimens that were given for 6 weeks resulted in high cure rates for HCV infection with excellent tolerability. Addition of a third potent direct-acting antiviral drug can reduce the duration of treatment required to achieve sustained viral response in patients with chronic HCV genotype 1 infection without cirrhosis.”

This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online  
[www.hepatitisc.uw.edu](http://www.hepatitisc.uw.edu)

Hepatitis Web Study  
<http://depts.washington.edu/hepstudy/>

Funded by a grant from the Centers for Disease Control and Prevention.